PDF factsheet

Z

antithrombotics in peripheral vascular diseases for all type of patients, clinical trials results

acenocoumarol versus placebo
APIC, 1989	Acenocoumarol INR 2-4.5 versus Placebo	AOMI syade II	Simple aveugle Follow-up duration: 1 an
aspirin versus placebo
CLIPS, 2007	oral aspirin 100 mg daily versus placebo	outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6	double blind Follow-up duration: 20.7 months mean Europe
HNF versus placebo
Tesi, 1989	HBPM 8000 U / j versus Placebo	AOMI stade II	Double aveugle Follow-up duration: 6 mois
Antonicelli, 1999	Héparine calcique 12500 IU / j versus Placebo	AOMI stade II	Double aveugle Follow-up duration: 3 mois
LMWH versus placebo
Mannarino, 1991	Héparine de bas poids moléculaire( PM= 5000 Dalton), 15000 U od sc versus Placebo en seringues préremplies de même aspect que le traitement	AOMI stade II	Double aveugle Follow-up duration: 6 mois
Calabro, 1993	Héparine de bas poids moléculaire versus Placebo	AOMI stade II	Double aveugle Follow-up duration: 6 mois
phenprocoumon versus placebo
De Smit, 1987	Phenprocoumon INR 2.8-4.8 versus Placebo	AOMI de stade II (stades III et IV : 7%)	Double aveugle Follow-up duration: 5 ans

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags